Themis Medicare Ltd Stock Price Today (NSE: THEMISMED)

Themis Medicare Ltd

102.64+1.14 (+1.12%)
Market Open

Fundamental Score

...

Themis Medicare Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Themis Medicare Ltd share price today is 102.64, up +1.12% on NSE/BSE as of 17 June 2026. Themis Medicare Ltd (THEMISMED) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of 969.87 (Cr). The 52-week high for THEMISMED share price is 148.00 and the 52-week low is 64.95. The company has a Return on Equity (ROE) of 7.65% and a debt-to-equity ratio of 0.25.

Themis Medicare Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
115.89
Low
90.81
Volume
96.6K
Change
+16.92%

Themis Medicare Ltd share price chart: 16.92% return over the past month. 52-week high ₹148.00, 52-week low ₹64.95.

Themis Medicare Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
105.01110.48104.58108.121.17L (Cr)
110.00110.89103.75105.3576.70K (Cr)
113.91117.50108.15109.561.43L (Cr)
107.80115.89107.80113.904.37L (Cr)
103.45108.1199.01106.462.42L (Cr)
101.99101.9999.42100.2429.18K (Cr)
99.13105.2698.00100.2990.27K (Cr)
98.9099.9997.8598.6430.81K (Cr)
97.46101.0096.2597.4647.33K (Cr)
96.76101.6596.7698.1458.55K (Cr)

Themis Medicare Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
110.00110.89103.75108.12-1.71%
98.60117.5094.43109.56+11.12%
67.00100.0067.0098.70+47.31%
82.0184.8964.9566.07-19.44%
77.5096.0075.1585.80+10.71%
101.91108.2976.0080.18-21.32%
109.40112.4098.02100.60-8.04%
124.80125.80101.15107.86-13.57%
135.50147.00123.00124.22-8.32%
97.60148.0097.60134.81+38.12%
107.11118.7997.5298.60-7.95%
130.95131.89106.68107.49-17.92%

Returns & Performance

Poor

Return on Equity (ROE)

7.65%

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

10.37%

Returns generated on total capital deployed

Excellent

Oper. Profit Margin (5Y Avg)

17.72%

Average operating profit margin over 5 years

Dividend Yield

0.48%

Annual dividend as % of current share price

Themis Medicare Ltd Valuation Check

Price to Earnings (P/E)

N/A

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

31.77x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

67.15%

% shares held by company founders/management

Poor

FII Holding

0.06%

% shares held by foreign institutional investors

Poor

DII Holding

0.01%

% held by domestic mutual funds, LIC, banks

Poor

Promoter Pledged %

2.43%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Poor

Profit Growth (Quarterly YoY)

-125.33%

Net profit growth vs same quarter last year

Poor

Revenue Growth (Quarterly YoY)

-33.35%

Revenue growth vs same quarter last year

Excellent

Revenue Growth (5-Year CAGR)

15.00%

Compounded annual revenue growth over 5 years

Poor

EPS Growth (5-Year CAGR)

3.88%

Earnings per share growth over 5 years

Poor

Net Profit Growth (5-Year CAGR)

3.91%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.25x

Total debt ÷ equity. Below 0.5 = financially healthy

Poor

Interest Coverage Ratio

-1.58x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

66.09 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Themis Medicare Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of THEMISMED across key market metrics for learning purposes.

Positive Indicators

5 factors identified

Strong Operating Margins (17.72%)

Observation: Healthy 5-year operating margins indicate pricing power and cost control.

Analysis: OPM >15% suggests operational efficiency and competitive advantages.

Consistent Growth Track Record (15.00% CAGR)

Observation: Strong 5-year sales compound annual growth rate.

Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.

Conservative Debt Levels (D/E: 0.25)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Strong Cash Generation (₹66.09 Cr over 5Y)

Observation: Healthy free cash flow generation supports growth and returns.

Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.

Balanced Promoter Holding (67.15%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Risk Factors

7 factors identified

Below-Average Return on Equity (7.65%)

Observation: Returns on equity are below industry benchmarks.

Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.

Profit Decline Concern (-125.33%)

Observation: Significant year-over-year profit contraction observed.

Analysis: Declining profitability requires investigation into underlying causes.

Revenue Contraction (-33.35%)

Observation: Sales decline may indicate market challenges or competitive pressures.

Analysis: Negative revenue growth requires analysis of market conditions.

Weak Earnings Growth (3.88% CAGR)

Observation: Below-average 5-year EPS growth performance.

Analysis: Low EPS growth may not keep pace with inflation.

Stagnant Profit Growth (3.91% CAGR)

Observation: Limited 5-year profit growth trajectory.

Analysis: Low profit growth may indicate scalability challenges or market maturity.

Weak Interest Coverage (-1.58x)

Observation: Limited ability to service debt obligations from earnings.

Analysis: Low interest coverage raises concerns about financial stability.

Limited Institutional Interest (FII+DII: 0.07%)

Observation: Low institutional participation may affect liquidity.

Analysis: Limited institutional interest may indicate size constraints or visibility issues.

Themis Medicare Ltd vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Themis Medicare Ltd with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
30/100
103
₹969.87
7.65%
Poor
10.37%
Average
0.3
Excellent
3.91%
Average
15.00%
Excellent
0.48%
65.2/100
1797
₹433738.68
37.6
Average
16.86%
Good
20.21%
Excellent
0.1
Excellent
23.78%
Excellent
9.87%
Good
0.89%
67.9/100
6554
₹170445.88
68.6
Average
15.35%
Good
20.44%
Excellent
0.0
Excellent
10.41%
Good
11.65%
Good
0.47%
65.3/100
4350
₹126430.62
58.4
Average
26.52%
Excellent
27.05%
Excellent
0.3
Excellent
13.84%
Good
7.72%
Good
0.86%
Cipla Ltd...
CIPLA500087
59/100
1390
₹123059.76
22.6
Average
17.77%
Good
22.72%
Excellent
0.0
Excellent
28.68%
Excellent
9.97%
Good
0.85%
59.2/100
1290
₹105224.96
18.2
Average
17.96%
Good
22.69%
Excellent
0.2
Excellent
22.28%
Excellent
13.26%
Good
0.63%
Lupin Ltd...
LUPIN500257
66.7/100
2263
₹95148.15
22.0
Average
20.62%
Excellent
21.30%
Excellent
0.3
Excellent
54.88%
Excellent
8.11%
Good
0.58%
68.7/100
1091
₹94253.78
18.7
Average
21.21%
Excellent
24.31%
Excellent
0.4
Excellent
25.92%
Excellent
10.27%
Good
1.17%
50.6/100
2320
₹92012.53
52.6
Average
14.68%
Average
15.98%
Good
0.6
Good
11.73%
Good
15.79%
Excellent
0.04%
28.8/100
1434
₹70798.69
20.7
Average
11.08%
Average
14.18%
Average
0.2
Excellent
3.87%
Average
6.55%
Good
0.33%
59.5/100
5315
₹67075.29
28.5
Average
19.39%
Good
20.38%
Excellent
0.2
Excellent
13.93%
Good
9.21%
Good
0.80%

Themis Medicare Ltd PE Ratio History

Historical price-to-earnings ratio for THEMISMED — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 20253.24₹100.6031x
FY 20244.72₹263.5555.8x
FY 20236.17₹213.7034.6x
FY 20227.91₹135.5017.1x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Themis Medicare Ltd Dividend History

Annual cash dividends paid by THEMISMED — dividend yield 0.48%

Financial YearDividends Paid (₹ Cr)
FY 20254.60 Cr
FY 20244.60 Cr
FY 20234.60 Cr
FY 20223.96 Cr

Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.

Themis Medicare Ltd Quarterly Performance

Latest quarterly metrics for THEMISMED — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

-33.35%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

-125.33%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

15.00%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

3.91%

Compounded annual net profit growth over 5 years

Themis Medicare Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for THEMISMED — calculated from daily price history

67RSI 14
Neutral — RSI 67

Momentum is balanced — neither overbought nor oversold.

SMA 50
89
▲ Price above SMA 50 — Short-term bullish
SMA 200
102
▲ Price above SMA 200 — Long-term uptrend
30-Day Avg Volume
95K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Themis Medicare Ltd Financial Statements

Annual income statement, balance sheet and cash flow for Themis Medicare Ltd (THEMISMED) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Themis Medicare Ltd

About THEMISMED (Themis Medicare Ltd)

Themis Medicare Ltd is a dynamic pharmaceutical company focused on developing, manufacturing, and marketing a diverse portfolio of pharmaceutical products. With a commitment to inn...ovation and quality, Themis Medicare caters to a broad spectrum of therapeutic needs, positioning itself as a significant player in both domestic and international markets. Their research and development efforts are geared towards creating effective and accessible medicines, with a strong emphasis on addressing prevalent health challenges. The company's strategic vision encompasses expanding its product line and strengthening its global footprint through strategic partnerships and collaborations, ensuring sustainable growth and value creation for its stakeholders. Themis Medicare distinguishes itself through a vertically integrated business model, encompassing the production of both active pharmaceutical ingredients (APIs) and finished formulations. This allows for greater control over the supply chain, ensuring consistent quality and cost-effectiveness. The company's product range includes medications targeting key therapeutic areas such as pain management, infectious diseases, diabetes, and cardiovascular health. By focusing on these critical areas, Themis Medicare aims to make a tangible difference in patient outcomes and contribute to improved public health. Its manufacturing facilities adhere to stringent international quality standards, further solidifying its reputation for reliability and excellence. Beyond its core business activities, Themis Medicare is deeply committed to ethical practices and corporate social responsibility. The company actively engages in initiatives aimed at improving access to healthcare and promoting health awareness within communities. By investing in research, technology, and human capital, Themis Medicare strives to remain at the forefront of the pharmaceutical industry, constantly adapting to evolving market demands and patient needs. This forward-thinking approach, coupled with a dedication to quality and innovation, positions Themis Medicare as a trusted provider of pharmaceutical solutions.

Company Details

Symbol:THEMISMED
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Dr. Dinesh Shantilal Patel CChem., FRSC(Lond.), Ph.D.
Executive Chairman
Dr. Sachin Dinesh Patel CChem., Ph.D.
CEO, MD & Executive Director
Mr. Tushar J. Dalal A.C.A.
Chief Financial Officer

Corporate Events

Recent
Ex-Dividend Date

THEMISMED Share Price: Frequently Asked Questions

What is the current share price of Themis Medicare Ltd?

Themis Medicare Ltd (THEMISMED) trades at ₹102.64 on NSE and BSE. Market cap ₹969.87 (Cr). Educational data only.

What is the P/E ratio of Themis Medicare Ltd?

Themis Medicare Ltd has a P/E of N/Ax vs industry average 31.77x.

What is the Bull Run score for Themis Medicare Ltd?

Themis Medicare Ltd has a Bull Run score of 30/100 based on 25+ financial parameters.

Does Themis Medicare Ltd pay dividends?

Themis Medicare Ltd has a dividend yield of 0.48%. Past dividends don't guarantee future payments.

What is the ROE of Themis Medicare Ltd?

Themis Medicare Ltd has ROE of 7.65%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Themis Medicare Ltd?

Themis Medicare Ltd has debt-to-equity of 0.25.

Is Themis Medicare Ltd a good investment?

Bull Run gives Themis Medicare Ltd a score of 30/100. This is not investment advice — consult a SEBI-registered advisor.